Publications by authors named "Louis Lacombe"

Article Synopsis
  • The study investigates the role of 11-oxygenated androgens, particularly 11-ketotestosterone (11KT), in predicting the progression of lethal prostate cancer and the onset of castration-resistant prostate cancer (CRPC).
  • Using mass spectrometry on blood samples from 145 patients treated with androgen deprivation therapy, researchers analyzed the relationship between androgen levels and CRPC development.
  • Findings suggest higher levels of 11KT are associated with a shorter time to CRPC, indicating that monitoring this hormone could enhance treatment strategies for prostate cancer patients.
View Article and Find Full Text PDF
Article Synopsis
  • This study looks at different types of immune cells in prostate cancer and how they affect the patient's chance of recovery.
  • Researchers used lab tests on cancer samples to find out which immune cells are present and how they relate to the severity of the disease.
  • They found that certain immune cell types and their amounts could predict if a patient would need more treatment or if the cancer could be deadly.
View Article and Find Full Text PDF
Article Synopsis
  • Scientists studied the estrogen receptor α (ERα) in prostate cancer and found it only appears in about half of the patients' tumors.
  • When ERα is present, it can affect how the cancer grows and spreads, and is linked to patients' chances of survival.
  • The research suggests that targeting ERα could be a new way to treat prostate cancer by changing how cancer cells use energy.
View Article and Find Full Text PDF

Objectives: To evaluate the International Society of Urological Pathology (ISUP) 5-tier grade grouping (GG) system of prostate cancers as well as previously proposed optimizations.

Patients And Methods: The PROCURE biobank is a prospective cohort study of patients with localized prostate cancer who underwent radical prostatectomy in Quebec province between 2005 and 2013. Surgical specimens were graded by experienced genitourinary pathologists using 2019 ISUP criteria.

View Article and Find Full Text PDF

Background: High prostate eicosapentaenoic fatty acid (EPA) levels were associated with a significant reduction of upgrading to grade group (GG) ≥ 2 prostate cancer in men under active surveillance. We aimed to evaluate the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation.

Methods: A phase II double-blind randomized placebo-controlled trial was conducted in 130 men diagnosed with GG ≥ 2 prostate cancer and undergoing radical prostatectomy between 2015-2017 (Clinicaltrials.

View Article and Find Full Text PDF

Introduction: Bacillus Calmette-Guérin (BCG) failure occurs in approximately 40% of patients with non-muscle-invasive bladder cancer (NMIBC) within two years. We describe our institutional experience with sequential intravesical gemcitabine and docetaxel (gem/doce) as salvage therapy post-BCG failure in patients who were not candidates for or declined radical cystectomy (RC).

Methods: We retrospectively reviewed NMIBC patients with BCG failure who received gem/doce from April 2019 through October 2022 at the CHU de Québec-Université Laval.

View Article and Find Full Text PDF

Background: In the general population, a higher omega-3 polyunsaturated fatty acids intake is associated with lower levels of several psychological symptoms, especially depression. However, the existing evidence in cancer is equivocal.

Methods: This phase IIB double-blind, placebo-controlled trial was aimed at comparing the effects of eicosapentaenoic acid monoacylglyceride (MAG-EPA) supplementation and high oleic acid sunflower oil (HOSO; placebo) on depression levels (primary outcome) and other symptoms (anxiety, fear of cancer recurrence, fatigue, insomnia, perceived cognitive impairments; secondary outcomes).

View Article and Find Full Text PDF

Background: Immunotherapy-based combinations including pembrolizumab plus lenvatinib are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these combinations are not well characterised in non-clear-cell renal cell carcinoma. We aimed to assess the activity and safety of pembrolizumab plus lenvatinib as a first-line treatment for patients with advanced non-clear-cell renal cell carcinoma.

Methods: KEYNOTE-B61 is a single-arm, phase 2 trial being conducted at 48 sites (hospitals and cancer centres) in 14 countries (Australia, Canada, France, Hungary, Ireland, Italy, Poland, South Korea, Russia, Spain, Türkiye, Ukraine, the UK, and the USA).

View Article and Find Full Text PDF

Introduction: Prostate cancer (PCa) shows considerable variation in clinical outcomes between individuals with similar diseases. The initial host-tumor interaction as assessed by detailed analysis of tumor infiltrating immune cells within the primary tumor may dictate tumor evolution and late clinical outcomes. In this study, we assessed the association between clinical outcomes and dendritic cell (DC) or macrophage (MΦ) tumor infiltration as well as with expression of genes related to their functions.

View Article and Find Full Text PDF

Intraductal carcinoma of the prostate (IDC-P) is an aggressive histological subtype of prostate cancer (PCa) detected in approximately 20% of radical prostatectomy (RP) specimens. As IDC-P has been associated with PCa-related death and poor responses to standard treatment, the purpose of this study was to explore the immune infiltrate of IDC-P. Hematoxylin- and eosin-stained slides from 96 patients with locally advanced PCa who underwent RP were reviewed to identify IDC-P.

View Article and Find Full Text PDF

The androgen receptor (AR) is an established orchestrator of cell metabolism in prostate cancer (PCa), notably by inducing an oxidative mitochondrial program. Intriguingly, AR regulates cytoplasmic isocitrate dehydrogenase 1 (IDH1), but not its mitochondrial counterparts IDH2 and IDH3. Here, we aimed to understand the functional role of IDH1 in PCa.

View Article and Find Full Text PDF

Prostate cancer (PCa) and associated treatments incur symptoms that may impact patients' quality of life. Studies have shown beneficial relationships between diet, especially omega-3 fatty acids, and these symptoms. Unfortunately, only few data describing the relationship between long-chain omega-3 fatty acids (LCn3) and PCa-related symptoms in patients are available.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how circulating levels of adrenal 11-oxygenated androgens affect clinical outcomes in men with newly diagnosed localized prostate cancer, focusing on their potential role in cancer progression.
  • Analysis was conducted on 1,793 treatment-naïve patients and 155 patients on 5α-reductase inhibitors, assessing the relationship between androgen levels and various prognostic indicators using advanced statistical models.
  • Results indicated that while higher levels of certain 11-oxygenated androgens correlated with worse cancer markers, they did not directly impact disease-free survival, but were linked to better metastasis-free survival for specific androgen precursors.
View Article and Find Full Text PDF
Article Synopsis
  • Naturally occurring deletions of the UGT2B17 and UGT2B28 genes impact the risk and progression of prostate cancer and other diseases.
  • Research analyzed metabolic changes in prostate cancer cases lacking these genes through advanced mass spectrometry methods.
  • Findings showed that these gene deletions significantly altered metabolic profiles, affecting over 5% of metabolites, which may influence tumor growth and inflammation in prostate cancer.
View Article and Find Full Text PDF

The androgen inactivating UGT2B28 pathway emerges as a predictor of progression in prostate cancer (PCa). However, the clinical significance of UGT2B28 tumoral expression and its contribution to PCa progression remain unclear. Using the Canadian Prostate Cancer Biomarker Network biobank (CPCBN; n = 1512), we analyzed UGT2B28 tumor expression in relation to clinical outcomes in men with localized PCa.

View Article and Find Full Text PDF

Objective: To evaluate whether differences exist between men and women in response to intravesical BCG treatments. The incidence of urothelial carcinoma of the bladder is lower in women but they tend to present with more aggressive and advanced disease. Some prior studies also suggest there are sex-based differences in response to treatment for non-muscle invasive bladder tumors.

View Article and Find Full Text PDF

Purpose: Dihydrotestosterone and testosterone are thought to be major contributors of prostate cancer progression and resistance. We studied the modulation of 15 circulating steroids by castration and their association with dihydrotestosterone and testosterone levels.

Materials Methods: A total of 116 serum samples were collected from 99 prostate cancer patients and categorized as eugonadal, castration-sensitive prostate cancer, castration-resistant prostate cancer, or castration-resistant prostate cancer under abiraterone acetate.

View Article and Find Full Text PDF

Background: CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucaparib.

Methods: CheckMate 9KD enrolled adult patients with histologically confirmed mCRPC, ongoing androgen deprivation therapy, and an Eastern Cooperative Oncology Group performance status of 0-1.

View Article and Find Full Text PDF

Prostate cancer (PCa) is the second most diagnosed cancer in the United States and is associated with metabolic reprogramming and significant disparities in clinical outcomes among African American (AA) men. While the cause is likely multi-factorial, the precise reasons for this are unknown. Here, we identified a higher expression of the metabolic enzyme UGT2B28 in localized PCa and metastatic disease compared to benign adjacent tissue, in AA PCa compared to benign adjacent tissue, and in AA PCa compared to European American (EA) PCa.

View Article and Find Full Text PDF

Introduction: During the first regional COVID-19 lockdown in March 2020, we conducted a study aimed at evaluating completeness of telemedicine consultation in urology. Of 1679 consultations, 67% were considered completely managed by phone. The aim of the present study was to assess patients' experience and satisfaction with telemedicine and to compare them with urologists' perceptions about quality and completeness of the telemedicine consultation.

View Article and Find Full Text PDF
Article Synopsis
  • The prostate produces a special substance called citrate that helps keep males fertile, but in prostate cancer, this process changes and is tricky to understand.!
  • Researchers studied mouse and human prostate cells in the lab to find out how citrate is made and discovered there are at least four different ways the prostate makes citrate, not just the one they thought before.!
  • Understanding these processes better could help with treating prostate cancer and improving male fertility in the future.!
View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied how sex hormones impact prostate cancer and its immune cells!
  • They found that hormones like androgens and estrogens can affect the way immune cells, particularly macrophages, behave around prostate tumors!
  • Understanding these effects could help doctors create better treatments for prostate cancer patients in the future!*
View Article and Find Full Text PDF

Detailed knowledge of the various venous anomalies is important to optimize the surgical approach and minimize catastrophic complications during retroperitoneal surgery. We report a rare case of an isolated left inferior vein cava (IVC) in a patient with left renal cell carcinoma with level IV IVC thrombus extension, which was successfully treated with terminal-lateral anastomoses between the left and right IVC. We also reviewed the types of duplicated IVCs and discussed the intraoperative management.

View Article and Find Full Text PDF

Background And Aims: Many dietary supplements, including omega-3 fatty acids (ω3), are suspected to affect blood coagulation and platelet function. Despite no clinical evidence, discontinuation is recommended before radical prostatectomy. However, long-chain ω3 (LCω3) appear beneficial against prostate cancer progression.

View Article and Find Full Text PDF